Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy

The advent of immunotherapy represents a significant breakthrough in cancer treatment, with immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 demonstrating remarkable therapeutic efficacy. However, patient responses to immunotherapy vary significantly, with immunosuppression within the tumor microenvironment (TME) being a critical factor influencing this variability. Immunosuppression plays a pivotal role in regulating cancer progression, metastasis, and reducing the success rates of immunotherapy. Myeloid-derived suppressor cells (MDSCs), due to their potent immunosuppressive capabilities, emerged as major negative regulators within the TME, facilitating tumor immune evasion by modulating various…

• NN
  National Natural Science Foundation of China

  Award: 32270954
• NU
  Nantong University
• CS
  Changzhou Science and Technology Bureau
• CI
  Changzhou Institute of Technology

  Award: CZ20230017
• WH
  Wuxi Health and Family Planning Commission

  Award: Q202357